NEWPORT NEWS, Va., June 2, 2011 /PRNewswire/ -- Dilon Diagnostics will introduce the latest advancement in molecular
MBI, also referred to as Breast-Specific Gamma Imaging (BSGI), is a functional imaging technique increasingly being used in the diagnostic workup of patients with indeterminate mammograms, particularly for those with dense breasts. With more than 250,000 patients imaged worldwide and an expanding number of molecular imaging products, Dilon is leading the forefront in molecular imaging and supporting clinical data for early cancer diagnostics. Dilon believes its continued success can, in part, be attributed to its focus on the individual needs of each healthcare facility and personalized healthcare by providing customers with ongoing advancements such as larger field-of-view detectors and products like GammaLoc® (the only FDA-cleared biopsy guidance platform for MBI).
According to Robert G. Moussa, Chairman and CEO at Dilon Diagnostics, "With the increasing need to better serve a diversifying population of women, we feel it is crucial to provide additional solutions to help facilities reduce tiling, examination times and ultimately, continue to optimize their workflow."
"With the launch of the Acella," said Moussa, "I am proud to say that we are now the only molecular breast imaging company in the industry who has the unique capability of being able to offer customers a choice of imaging solutions."
About Dilon Diagnostics
Dilon Diagnostics, a brand of Dilon Technologies Inc., is bringing innovative new medical imaging products to market. Dilon's cornerstone product, the Dilon 6800®, is a high-resolution, small field-of-view digital gamma camera, optimized for breast imaging (MBI/BSGI). MBI utilizes radiotracer uptake to detect the increased metabolic activity of breast lesions and therefore, is not affected by breast density. Both the Dilon 6800 and Acella systems provide the high photon sensitivity needed to perform low dose MBI/BSGI studies. Dilon's GammaLoc® System is the only localization device on the market to enable gamma-guided breast biopsy. Many leading medical centers around the country are now offering BSGI to their patients, including: Cornell University Medical Center, New York; Lahey Clinic, Boston; George Washington University, Washington D.C. For more information on Dilon Diagnostics please visit www.dilon.com.
SOURCE Dilon Diagnostics
Subscribe to our Free Newsletters!